WOBURN, MA & ATLANTA, GA (September 20, 2021) – Azurity Pharmaceuticals, Inc. (“Azurity”) is pleased to announce the closing of its acquisition of Arbor Pharmaceuticals, Inc. (“Arbor”), as previously announced on August 24, 2021. The acquisition creates a leading company offering innovative, high-value products to meet the unique needs of patients with underserved conditions.
With this acquisition, Arbor is now a wholly-owned subsidiary of Azurity. The two companies will begin to integrate their operations over the coming months and will operate as Azurity post-integration.
About Azurity Pharmaceuticals:
Azurity Pharmaceuticals is a privately-held, specialty pharmaceutical company focusing on the needs of patients requiring customized, user-friendly drug formulations and dosage forms. Azurity’s patient centric products span the cardiovascular, neurology, gastro-intestinal and institutional markets. Azurity’s products have benefited millions of patients for which conventional oral dosage forms are not ideal and whose needs are not served by other commercially available therapies. For more information, visit www.azurity.com.
About Arbor Pharmaceuticals:
Arbor Pharmaceuticals, headquartered in Atlanta, Georgia, is a specialty pharmaceutical company marketing FDA-approved prescription products in the neuroscience, cardiovascular, and institutional markets. In addition to an extensive pipeline, the company actively pursues growth through acquisition and licensing of late-stage development products. For more information, visit www.arborpharma.com.